CellaVision AB (SE:CEVI)
:CEVI
Want to see SE:CEVI full AI Analyst Report?
CEVI Stock Chart & Stats
kr161.00
-kr3.60(-2.10%)
At close: 4:00 PM EST
kr161.00
-kr3.60(-2.10%)
Day’s Range― - ―
52-Week Rangekr120.00 - kr208.00
Previous CloseN/A
Volume5.79K
Average Volume (3M)36.08K
Market Cap
kr2.92B
Enterprise Valuekr2.72B
Total Cash (Recent Filing)kr230.22M
Total Debt (Recent Filing)kr22.43M
Price to Earnings (P/E)40.7
Beta0.87
Next Earnings
Jul 21, 2026EPS Estimate
1.41Next Dividend Ex-DateN/A
Dividend Yield1.61%
Share Statistics
EPS (TTM)0.92
Shares Outstanding23,851,547
10 Day Avg. Volume30,505
30 Day Avg. Volume36,083
Financial Highlights & Ratios
PEG Ratio2.78
Price to Book (P/B)4.22
Price to Sales (P/S)4.94
P/FCF Ratio20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.17
Revenue Forecast (FY)kr823.52M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExceptionally low leverage and a large equity base provide durable financial flexibility. This supports continued R&D investment, dividend increases and the ability to fund product launches or local manufacturing requirements without pressure on operations or the need for dilutive financing.
Sustained High MarginsVery high gross and healthy net margins indicate structural pricing power and efficient product mix in digital microscopy. Margin durability supports reinvestment in R&D and sales, underpins free-cash-flow potential over time, and cushions against cyclical revenue swings.
Regulatory & Product AdvancesCE marking and validated software improvements are structural product milestones that expand the addressable market and strengthen the installed-base value proposition. These enhance long-term upsell opportunities for reagents, service and bundled instrument upgrades.
Bears Say
Recent Revenue SoftnessA TTM revenue decline signals a near-term growth pause that can slow installed-base expansion and follow-on recurring revenue from software and reagents. If sustained, this could delay the expected payoff from new product launches and pressure medium-term top-line momentum.
Weakened Free Cash Flow ConversionA sharp drop in free-cash-flow conversion suggests higher investment needs or working-capital drag. Lower cash conversion reduces excess liquidity for M&A, buybacks or faster dividend growth and makes funding new launches or commercialization more reliant on the balance sheet.
Execution & Regional Tender VolatilityLarge APAC swings tied to tender timing and shipment phasing create structural unpredictability in regional revenue. Combined with product-mix and FX headwinds that pressured margins, this raises execution risk for near-term revenue and margin sustainability across key growth markets.
CellaVision AB News
CEVI FAQ
What was CellaVision AB’s price range in the past 12 months?
CellaVision AB lowest stock price was kr120.00 and its highest was kr208.00 in the past 12 months.
What is CellaVision AB’s market cap?
CellaVision AB’s market cap is kr2.92B.
When is CellaVision AB’s upcoming earnings report date?
CellaVision AB’s upcoming earnings report date is Jul 21, 2026 which is in 82 days.
How were CellaVision AB’s earnings last quarter?
CellaVision AB released its earnings results on Apr 24, 2026. The company reported kr0.92 earnings per share for the quarter, missing the consensus estimate of kr1.544 by -kr0.624.
Is CellaVision AB overvalued?
According to Wall Street analysts CellaVision AB’s price is currently Overvalued.
Does CellaVision AB pay dividends?
CellaVision AB pays a Annually dividend of kr2.5 which represents an annual dividend yield of 1.61%. See more information on CellaVision AB dividends here
What is CellaVision AB’s EPS estimate?
CellaVision AB’s EPS estimate is 1.41.
How many shares outstanding does CellaVision AB have?
CellaVision AB has 23,851,547 shares outstanding.
What happened to CellaVision AB’s price movement after its last earnings report?
CellaVision AB reported an EPS of kr0.92 in its last earnings report, missing expectations of kr1.544. Following the earnings report the stock price went down -21.541%.
Which hedge fund is a major shareholder of CellaVision AB?
Currently, no hedge funds are holding shares in SE:CEVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellaVision AB
CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
CEVI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and financial picture: solid revenue and organic growth, a strong EBITDA margin above target, record Americas performance, important strategic progress (bone marrow CE Mark, software validation, DI-60 throughput improvements), a healthy cash position and a proposed dividend increase. Offsetting factors include a weak APAC quarter driven by comparables and tender timing, softness in reagents/software mix that pressured Q4 gross margin, FX headwinds, and near-term uncertainty on revenue ramp from new product launches (bone marrow and U.S. methanol-free reagents). Overall these negatives appear manageable against the company’s clear commercial momentum and strategic milestones.View all SE:CEVI earnings summariesTechnical Analysis
BICO Group AB Class B
―
Senzime AB
―
Xvivo Perfusion AB
―
C-Rad AB Class B
―
Sedana Medical AB
―
Options Prices
Currently, No data available
---